Director/PDMR Share Dealings

Creo Medical Group PLC
21 October 2024
 

 

 

LEI: 213800H188ZDCWWXFA21

 

 

21 October 2024

 

Creo Medical Group plc

("Creo" or the "Company")

 

Director/PDMR Share Dealings

 

Further to the announcements made on 30 September 2024 and 18 October 2024, and pursuant to the recent fundraising, the Company confirms that the following directors of the Company have acquired New Ordinary Shares at the Issue Price of 24 pence per Ordinary Share as follows:

 

 

Director/PDMR Name

No. of New Ordinary Shares Acquired

Resultant Shareholding post transaction

% of voting rights post transaction

Kevin Crofton

2,916,666

3,566,666

0.87%

Richard Rees

208,333

3,036,540

0.74%

 

 

 

Creo Medical Group plc

www.creomedical.com

Richard Craven, Company Secretary

Via Walbrook PR



Cavendish Capital Markets Limited

(Nominated Adviser, Joint Bookrunner and Joint Broker)

 

+44 (0)20 7220 0500

Stephen Keys / Camilla Hume / George Lawson (NOMAD)


Michael Johnson (Sales)

 




Deutsche Numis (Joint Bookrunner and Joint Broker)

Freddie Barnfield / Duncan Monteith / Euan Brown

William Baunton (ECM)

 

+44 (0)20 7260 1000

 


Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus / Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

 




 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Kevin Crofton

2

Reason for the notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of £0.001 each


Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

£0.24

2,916,666

d)

Aggregated information

N/A single transaction


Aggregated volume

N/A single transaction


Price

N/A single transaction

e)

Date of the transaction

21 October 2024

f)

Place of the transaction

London Stock Exchange

 

 

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Richard Rees

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of £0.001 each


Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

£0.24

208,333

d)

Aggregated information

N/A single transaction


Aggregated volume

N/A single transaction


Price

N/A single transaction

e)

Date of the transaction

21 October 2024

f)

Place of the transaction

London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings